M Pharmaceutical Inc. Appoints President of U.S. Operating Company Based In Greater Cincinnati

VANCOUVER, BC / ACCESSWIRE / August 2, 2016 / M-Pharmaceutical Inc., (CSE: MQ, OTCQB: MPHMF, FWB: T3F2 ), (the “Company” or “M Pharma”), announced it has appointed Mr. Gary Thompson of Fort Thomas, Kentucky to serve as President of the Company’s wholly owned subsidiary, M Pharmaceutical USA Inc., and oversee the production, testing and regulatory approval program for M Pharmaceutical’s C-103 project, M Pharmaceutical’s recently acquired reformulated Orlistat drug technology.

Mr. Brian Keane, President of the M Pharmaceutical Inc. noted that “Gary has been intimately involved in the creation of C-103, and has the experience to oversee the various steps needed over the next twelve to twenty-four months to get this drug to market. We look forward to working with him to achieve this goal.”

Gary A. Thompson, President of M-Pharmaceutical U.S.A. Inc., has over 30 years of sales and management experience in Fortune 500 health care organizations and startup pharmaceutical companies. He has served as Vice President of sales for Cigna Healthcare managing billions of assets over his career. Most recently, he has had management and leadership roles at several start up ventures that have obtained issued patents for innovative technology, including ToConceive LLC. (FDA approved) in women’s health and wellness and in the obesity space as president of Chelatexx LLC, from whom the Company acquired its C-103 reformulated Orlistat. He is a graduate of Northern Kentucky University, with a BS in Kinesiology. Gary is also a director of 501(c)(3) Non-Profit organization, Nehemiah Vision Ministries based in Chambrun, Haiti.

“The experience of the team and the resources that M-Pharmaceutical Inc. provides will allow us to expand our efforts to make C-103 available to the many people whom it can benefit greatly,” said Mr. Thompson. “I am excited to contribute my leadership to the company in order to bring this drug technology to market and make a difference in the lives of so many people.”

About M-Pharmaceutical Inc.

Formed in early 2015, M-Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of Orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights.

M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”

For more information contact:

Investor Relations
Phone: +1 604 428 0511
info@m-pharma.ca
www.m-pharma.ca

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to its biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

SOURCE: M-Pharmaceutical Inc.

ReleaseID: 443104